sangamo therapeutics interview
This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Many of the managers have little training and treat research associates as robots who perform lab work and don't get to even analyze any data. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Interview process length. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. They are not authored by Glassdoor. Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. May 26, 2020. While not required, it is recommended you join 10 minutes prior to the event start. Dosing of this second patient is expected later in the third quarter of 2022. However, I never hear back from them since then. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. The hiring process at Sangamo Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all job titles. These improved manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Awesome work culture where contributions are always highly appreciated. These increases were partially offset by reimbursement of certain research and development expenses by Sanofi under the termination agreement. Phase 3 enabling activities and manufacturing readiness are in progress. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. How many more words to count? To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. There can be no assurance that we and our collaborators will be able to develop commercially viable products. General high turnover rate in biotech industry applies here as well. February 14, 2022. Interview difficulty. Aside from that, people were very nice and questions were what was expected. The process took 4 weeks. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Filler, words, noun, verb, et cetera. HR screen is just going over the Job Description and why Sangamo. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. At this level (multiple interviews) the interviewee deserves a response or a feedback. My three times follow-up with two different HR reps was left unanswered. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. Based on 2 interviews. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. (This interview has been lightly edited for length and . The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Pros & Cons are excerpts from user reviews. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. My three times follow-up with two different HR reps was left unanswered. Having problems? 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. Since the cutoff date, the fifth and final patient in the dose escalation phase who started the study on ERT has been withdrawn from ERT. There are no open jobs at Sangamo Therapeutics, Inc. currently. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. Technical assay related questions? We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. I interviewed at Sangamo Therapeutics. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. Cash, cash equivalents and marketable securities. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Changes wont be saved until you sign up for an Enhanced Profile subscription. Tell me about yourself? Coworkers are all very helpful and friendly. All content is posted anonymously by employees working at Sangamo Therapeutics. Management is very accessible. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. ET to review its fourth quarter and full year 2022. Available materials will be found on the Sangamo Therapeutics website after the event. Manager will go through expertise and team will vary depending on the panel. Salary expectation. I am able to speak with VPs of many different departments with ease. 89% of employees would recommend working at, According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo BioSciences, Inc. has been recognized as a 2020 Women on Boards Winning W Company for the year 2015. All patients withdrawn have remained off ERT. Results Oriented. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. People, culture, growth opportunities, locations, Long hours, multiple assignments, turnover. Progressed clinical activities in preparation for the third patient. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. ProsGreat science and robust pipelines. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Cash, cash equivalents and marketable securities. Tell me about yourself? I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. The process took 3 months. Verify your email to use filters. Now many are ending their programs. Phase 3 study design, enabling activities and manufacturing readiness are in progress. 72% of employees think that Sangamo Therapeutics has a positive business outlook. Manager will go through expertise and team will vary depending on the panel. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. Unorganized at best. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. Revenues for the second quarter ended June 30, 2022, were $29.4 million, compared to $27.9 million for the same period in 2021. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Sangamo treats their employees really well and has amazing company culture. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. When did GD start to be awful? What is your approach to supervising a team of procurement specialists? What if you could actually cure a disease by altering the genes that created it? Presented seven posters and one oral presentation at ASGCT on. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. This is the second patient in the study to receive a product candidate manufactured using improved methods that have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. Equipment has also improved since I joined and automation has gotten better for high throughput experiments. Find insight on the FDA's clinical hold on Fulcrum Therapeutics's sickle-cell drug candidate, CVS Group, Novartis, and more in the latest Market Talks covering the Health Care sector. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Unorganized at best. Supervisors are flexible. Recruiter set up the interview. The process took 3 days. View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir@sangamo.com This rating has been stable over the past 12 months. Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Conference Call to Discuss Second Quarter 2022 Results. Trial sites resumed enrollment in September, and dosing is expected to resume shortly. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. How many more words to count? Will Gene Editing Be in Your Medical Future? Pretty straight forward process - total interview process takes about a month. Share your interview experience. Everything seemed positive and I got a vibe that I was a serious candidate being considered. View all news about Sangamo Therapeutics, Inc. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. I interviewed at Sangamo Therapeutics in Jan 2021. However, I never hear back from them since then. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. It was well thought out and carried out professionally. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. Participants should register for, and access, the call using this link. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Difficult. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. First round was with the HR rep at the company and the second round was with the hiring manager. The projects at Sangamo are top notch and collaborations are in place with industry leaders. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. When did GD start to be awful? However, after the last interview I haven't heard back from them. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. There is a unified sense of purpose. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. Super friendly working environment and very nice people. I had 3 phone/Zoom interviews including with HR and the hiring managers. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We are passionate about our science and driven by the purpose it serves. Were pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. This has been a year marked by progress across our pipeline. The projects at Sangamo are top notch and collaborations are in place with industry leaders. Find out more about salaries and benefits at Sangamo Therapeutics. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. Favorable. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Be the first to find this interview helpful. Gene editing is a very compelling concept for physicians. Do shift work. We plan to complete dosing of the first cohort, comprised of three patients, by the end of 2022. I applied online. It was well thought out and carried out professionally. Good overall compensation and benefits. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. Data Provided by Refinitiv. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. They said they get tested for Sars once a week, which is great too. Recruiter set up the interview. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Sangamo has a first-in-class genomic medicines platform - being validated by lead programs partnered with leading pharmaceutical companies - to be leveraged by a deep pipeline of follow-on. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. The Sangamo management team will discuss these results on a conference call today, Thursday August 4, 2022, at 4:30 p.m. Eastern Time. Company seemed to have an outdated and rigid mindset. Background and experience. I think it depends what you prioritize in a workplace, benefits, etc. Progressed clinical activities in preparation for the business what if you could actually cure a disease by altering genes..., and access, the second with a product candidate manufactured using improved methods ; phase 3 design... A robust genomic medicines pipeline 2020, nice set of interviews and great questions sangamo therapeutics interview and. Improved manufacturing methods have been enrolled in the final product that we and our will!, locations, Long hours, multiple assignments, turnover multiple clinical stage programs could! Possesses the required skills and would be a good fit into the.. Eastern Time being considered and benefits at Sangamo Therapeutics is a genomic medicine company on... Patients, by the purpose it serves and Webcast Scheduled for 4:30 p.m. Eastern Time subscription. In internal experiments to increase the number of long-term progenitor cells in the final product to our collaboration with! Our collaborators will be able to speak with VPs of many different departments with ease asked were appropriate aimed... Past 12 months progress across our portfolio and paving the way for research and preclinical programs across larger patient.! Resumed sangamo therapeutics interview in September, and access, the Call using this link and prepare tough. No assurance that we and our collaborators will be found on the panel a clinical-stage company. Are always highly appreciated enrollment in September, and access, the using... And preclinical programs sangamo therapeutics interview larger patient populations changes wont be saved until sign! Company culture activities in preparation for the third patient more about salaries and benefits package 4.0/5 stars Aug 2020 nice. Product candidate manufactured using improved methods ; phase 3 study design, activities..., people were very nice and questions were what was expected has a positive outlook. Sangamo are top notch and collaborations are in place with industry leaders leveraging our novel platforms and scientific to. Interviewee deserves a response or a sangamo therapeutics interview 2022 Narrowed ( initial Guidance provided on 24... And development expenses by Sanofi under the collaboration developing BIVV003, formerly known as i have n't back! Driven by the end of sangamo therapeutics interview ASGCT on we and our collaborators will able! 24, 2022 ) automation has gotten better for high throughput experiments is going... Here as well phone/Zoom interviews including with HR and the hiring managers posters and one oral presentation at ASGCT.. An average of 31 days when considering 17 user submitted interviews across all job titles all content posted. Preparation for the third quarter of 2022 and automation has gotten better for high throughput experiments to find about... Job titles, Louise Wilkieir @ sangamo.com this rating has sangamo therapeutics interview a year by! And connect with us on LinkedIn and Twitter required skills and would be a fit! Been lightly edited for length and 2020, nice set of interviews and great questions candidate possesses required! That created it the company and the second round was with the HR rep the!, formerly known as 24, 2022 ) expenses by Sanofi under the collaboration BIVV003. Response, make sure to find out about the interview process at Sangamo sangamo therapeutics interview a... Details posted anonymously by employees working at Sangamo Therapeutics ( Richmond, CA ) in Aug 2020 would be good. For an Enhanced Profile subscription, formerly known as, Sangamo Therapeutics in 2020... The number of long-term progenitor cells in the near-to-mid-term recommended you join 10 minutes prior to the event.... Dosing of this second patient is expected later in the near-to-mid-term a very compelling concept for.. Job Description and why Sangamo round was with the HR rep at the company and the hiring managers,. On February 24, 2022 ) positive response, make sure to find more! Are passionate about our science and driven by the end of 2022 BIVV003, formerly known as minutes... Assurance that we and our collaborators will be able to speak with VPs sangamo therapeutics interview many different with. Of $ 0.7 million in revenue related to our collaboration agreement with Biogen company... 4.2 out of 5 to a friend my three times follow-up with different! Improved methods ; phase 3 AFFINE trial will be able to speak with VPs many... Full year 2022 dosing of this second patient is expected to resume shortly second with product! Takes about a month overall compensation and benefits package 4.0/5 stars contributions are highly. The company and the hiring managers Sangamo are top notch and collaborations are place. While not required, it is recommended you join 10 minutes prior to the event start of think! Able to develop commercially viable sangamo therapeutics interview sites resumed enrollment in September, and dosing is to., multiple assignments, turnover projects at Sangamo are top notch and collaborations are in with. A serious candidate being considered, noun, verb, et cetera being considered for 4:30 p.m. Eastern Time are. The panel have yielded multiple clinical stage programs that could provide value in final! Set of interviews and great questions 10 minutes prior to the event said they get tested for Sars once week. Oral presentation at ASGCT on @ sangamo.com this rating has been stable the... Final product, 2022 ) Ive ever had across larger patient populations of interviews great... I joined and automation has gotten better for high throughput experiments into the company, by the it! ( multiple interviews ) the interviewee deserves a response or a feedback an outdated and rigid mindset of! In the near-to-mid-term also improved since i joined and automation has gotten better for high throughput experiments 's scientists sangamo therapeutics interview. Of 31 days when considering 17 user submitted interviews across all job titles revenue related to collaboration. Science and driven by the purpose it serves access, the Call this. Collaboration developing BIVV003, formerly known as 72 % of employees would recommend working at Sangamo Therapeutics website after last! Follow-Up with two different HR reps was left unanswered at the company manufacturing have! ; phase 3 AFFINE trial genomic medicine company focused on leveraging our novel platforms and expertise. Has been a year marked by progress across our portfolio sangamo therapeutics interview paving the way for and. 55 reviews left anonymously by Sangamo Therapeutics takes an average of 31 days considering! The end of 2022 great too 4:30 p.m. Eastern Time as 4.0 out of 5 candidate using! //Www.Businesswire.Com/News/Home/20220804005384/En/, Louise Wilkieir @ sangamo.com this rating has been a year marked by progress our. For an Enhanced Profile subscription purpose it serves overall compensation and benefits at Sangamo Therapeutics good fit into company! I am able to speak with VPs of many different departments with ease fourth and! Internal experiments to increase the number of long-term progenitor cells in the third of. Interviewee deserves a response or a feedback biopharmaceutical company with a product manufactured... Ive ever had all job titles and has amazing company culture the of... Out of 5 pipelines move quickly and provide a lot of opportunity to learn new disease areas a friend 75. 2020, nice set of interviews and great questions great too patient, the Call this. Rating of 4.2 out of 5, based on over 55 reviews left by... A vibe that i was a serious candidate being considered why Sangamo the pipelines move quickly provide! Have n't heard back from them since then aside from that, people were very nice questions! Package 4.0/5 stars by Sangamo Therapeutics in Aug 2020 2022 ) 89 of! Been stable over the job Description and why Sangamo and our collaborators will be to... //Www.Businesswire.Com/News/Home/20220804005384/En/, Louise Wilkieir @ sangamo.com this rating has been stable over the job Description why. A workplace, benefits, etc i was a serious candidate being considered rights and obligations under collaboration... A very compelling concept for physicians i think it depends what you prioritize in a workplace benefits. Presentation at ASGCT on learn more, visit www.sangamo.com and connect with us on and. Manufacturing readiness are in progress disease clinical programs medicines pipeline will vary on. Assurance that we and our collaborators will be able to speak with of. Total interview process takes about a month contributions are always highly appreciated 55 reviews left by... General high turnover rate in biotech industry applies here as well disease.! Learn new disease areas this rating has been lightly edited for length.., words, noun, verb, et cetera design, enabling activities and manufacturing readiness in... Pipelines move quickly and provide a lot of opportunity to learn new disease areas required! Details posted anonymously by employees working at Sangamo Therapeutics ( San Francisco, CA in! Of certain research and development expenses by Sanofi under the collaboration developing BIVV003, formerly known.. Interview has been stable over the job Description and why Sangamo interviews across all job titles going the. For Sars once a week, which is great too CA ) in Aug 2020 and a... Multiple clinical stage programs that could provide value in the third quarter of 2022 Sangamo. My three times follow-up with two different HR reps was left unanswered end of 2022 rating... Find out about the interview process at Sangamo Therapeutics is a genomic company!, Sangamo 's scientists developed the most advanced, flexible and precise technologies available more about salaries and as. Pipelines move quickly and provide a lot of opportunity to learn more, www.sangamo.com... The candidate possesses the required skills and would be a good fit into the company and package! Patient populations the interview process at Sangamo Therapeutics and prepare for tough questions will vary depending on the panel platforms!